Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has 10 years of Other Accumulated Expenses data on file, last reported at $3.4 million in Q3 2025.

• Other Accumulated Expenses for Q3 2025 came in at $3.4 million, down 90.73% year-over-year; the trailing twelve-month figure through Sep 2025 was $3.4 million (down 90.73% YoY), and the FY2024 annual result was $37.7 million, up 596.93% from the prior year.
• Other Accumulated Expenses slipped to $3.4 million in Q3 2025 per RYTM's latest filing, from $40.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $40.0 million in Q2 2025 and troughed at $229000.0 in Q1 2021.
• A 5-year average of $10.4 million and a median of $3.4 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses jumped 876.15% in 2024, then plunged 90.73% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $800000.0 in 2021, then jumped by 202.38% to $2.4 million in 2022, then jumped by 123.65% to $5.4 million in 2023, then surged by 596.93% to $37.7 million in 2024, then tumbled by 90.99% to $3.4 million in 2025.
• Business Quant data shows RYTM's Other Accumulated Expenses at $3.4 million in Q3 2025, $40.0 million in Q2 2025, and $38.8 million in Q1 2025.